Thursday May 25th 2017

Archive for February, 2012

Health minister tries to block bill backing controversial MS therapy

Health minister tries to block bill backing controversial MS therapy

Health Minister Leona Aglukkaq has sparked anger by aggressively opposing a private member’s bill that would accelerate clinical trials of so-called liberation therapy for people with multiple sclerosis. The private member’s bill, sponsored by Liberal MP Kirsty Duncan, [Read More]

Application closes for MS Liberation treatment study in New York

Application closes for MS Liberation treatment study in New York

For hundreds Multiple Sclerosis patients in Saskatchewan the next few months will be spent waiting. On Friday, February 24 the deadline closed for the provincially funded MS Liberation Treatment trial in Albany, New York. The government received 682 applications to be part [Read More]

MS trial in Saskatchewan attracts nearly 700 patients

MS trial in Saskatchewan attracts nearly 700 patients

Saskatchewan multiple sclerosis patients hoping to take part in a clinical trial of a controversial treatment may soon get a call from the ministry of health. But only around 10 per cent of those who applied will actually get that call. Deb Jordan, a ministry spokeswoman, [Read More]

 Page 1 of 5  1  2  3  4  5 »

Latest Topics

MS Study Alert: Share Your Thoughts About MS Research

MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of [Read More]

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of [Read More]